Oncology
Company plans to initiate a Phase 1 clinical study by 1H2026 and share data in 2027 Excerpt from the Press Release: PALO ALTO, Calif.–(BUSINESS WIRE)–NEOK Bio, Inc., an oncology therapeutics company focused on the development of novel antibody drug conjugates (ADCs) for improving outcomes for cancer patients, announced that the U.S. Food and Drug Administration…
GT Biopharma targets a portion of the estimated $362 billion global solid tumor market Preliminary, unaudited cash balance of approximately $7 million as of December 31, 2025 anticipated to extend cash runway into Q3 2026 Excerpt from the Press Release: SAN FRANCISCO, CALIFORNIA, Jan. 15, 2026 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (the “Company”) (NASDAQ:…
Excerpt from the Press Release: CAMBRIDGE, Mass., Dec. 12, 2025 /PRNewswire/ — Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision immunotherapy for oncology and inflammation & immunology (I&I), today unveiled initial clinical results from its ongoing STARt-002 phase 1b/2 trial during a late breaking presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS)…
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) — BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced late-breaking preclinical data on BBO-10203, a first-in-class covalent small molecule RAS:PI3Kα breaker that selectively and specifically blocks the physical interaction between RAS and…
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 /PRNewswire/ — IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced it has completed its targeted full enrollment of 435 patients in the registration-enabling Phase 2/3 trial (OptimUM-02) evaluating darovasertib, the company’s investigational oral protein kinase C (PKC) inhibitor,…
Phase 1 study advances A9-3408, an Actinium-225-based radiotherapeutic, building on the progress of the company’s imaging agent, A9-3202, which entered the clinic last year Robert Meehan, M.D., appointed as Chief Medical Officer, bringing extensive clinical development expertise to advance the Company’s radiotherapeutic pipeline Excerpt from the Press Release: BOSTON and VANCOUVER, BC, Dec. 4, 2025…
– The collaboration will leverage General Proximity’s OmniTAC™ platform to identify and advance next generation induced proximity agents for high value oncology targets. – Induced proximity medicines, powered by the OmniTAC™ platform, enable precise modulation of disease-driving and traditionally undruggable proteins. – General Proximity will identify novel effector-target pairs that can be exploited through induced proximity medicines.…
Excerpt from the Press Release: BOSTON and SINGAPORE, Nov. 06, 2025 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, and ImmunoScape, Pte. Ltd, a biotechnology company developing next-generation T…
Company Appoints Distinguished UCLA Oncology Surgeon to SAB, Enhancing Board’s Expertise in Surgical Oncology and Translational Oncology Research Aimed at Improving Multidisciplinary Treatment Strategies Excerpt from the Press Release: MOUNTAIN VIEW, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) — RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies…
Excerpt from the Press Release: TAIPEI, SHANGHAI and SAN FRANCISCO, Oct. 23, 2025 /PRNewswire/ — HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies, today announced that its manuscript describing the discovery and preclinical development of HCB101, an engineered SIRPα-Fc fusion protein, has been published in the Journal of Hematology & Oncology…